Pages that link to "Q35747277"
Jump to navigation
Jump to search
The following pages link to A cytokine and angiogenic factor (CAF) analysis in plasma for selection of sorafenib therapy in patients with metastatic renal cell carcinoma (Q35747277):
Displaying 50 items.
- Trial Watch (Q24618653) (← links)
- State of the science: an update on renal cell carcinoma (Q24630685) (← links)
- Molecular marker for predicting treatment response in advanced renal cell carcinoma: does the promise fulfill clinical need? (Q26825512) (← links)
- Circulating biomarkers in advanced renal cell carcinoma: clinical applications (Q27023770) (← links)
- Predictive and prognostic biomarkers of targeted agents and modern immunotherapy in renal cell carcinoma (Q28067482) (← links)
- Prostate cancer cell-stromal cell crosstalk via FGFR1 mediates antitumor activity of dovitinib in bone metastases (Q28247245) (← links)
- Analyses of potential predictive markers and survival data for a response to sunitinib in patients with metastatic renal cell carcinoma (Q30671049) (← links)
- Sunitinib-associated hypertension and neutropenia as efficacy biomarkers in metastatic renal cell carcinoma patients (Q33426958) (← links)
- Rapid angiogenesis onset after discontinuation of sunitinib treatment of renal cell carcinoma patients (Q33588739) (← links)
- Genomic Analysis as the First Step toward Personalized Treatment in Renal Cell Carcinoma (Q33947929) (← links)
- Investigation of novel circulating proteins, germ line single-nucleotide polymorphisms, and molecular tumor markers as potential efficacy biomarkers of first-line sunitinib therapy for advanced renal cell carcinoma (Q34243444) (← links)
- Microvessel area as a predictor of sorafenib response in metastatic renal cell carcinoma (Q34658963) (← links)
- Biomarkers for anti-angiogenic therapy in cancer. (Q34695003) (← links)
- Predicting response to bevacizumab in ovarian cancer: a panel of potential biomarkers informing treatment selection (Q34916073) (← links)
- A systematic review of the efficacy and safety experience reported for sorafenib in advanced renal cell carcinoma (RCC) in the post-approval setting (Q35591889) (← links)
- CECs and IL-8 Have Prognostic and Predictive Utility in Patients with Recurrent Platinum-Sensitive Ovarian Cancer: Biomarker Correlates from the Randomized Phase-2 Trial of Olaparib and Cediranib Compared with Olaparib in Recurrent Platinum-Sensitiv (Q35669792) (← links)
- Immunotherapy of genitourinary malignancies (Q35865051) (← links)
- Hypertension and Circulating Cytokines and Angiogenic Factors in Patients With Advanced Non-Clear Cell Renal Cell Carcinoma Treated With Sunitinib: Results From a Phase II Trial (Q36116324) (← links)
- A phase I trial and pharmacokinetic study of aflibercept (VEGF Trap) in children with refractory solid tumors: a children's oncology group phase I consortium report (Q36243701) (← links)
- Overexpression of c-Jun contributes to sorafenib resistance in human hepatoma cell lines (Q36316437) (← links)
- The distinct signatures of VEGF and soluble VEGFR2 increase prognostic implication in gastric cancer (Q36420167) (← links)
- Correlation of angiogenic biomarker signatures with clinical outcomes in metastatic colorectal cancer patients receiving capecitabine, oxaliplatin, and bevacizumab (Q36804893) (← links)
- Prognostic Biomarkers for Response to Vascular Endothelial Growth Factor-Targeted Therapy for Renal Cell Carcinoma. (Q36893510) (← links)
- Translational predictive biomarker analysis of the phase 1b sorafenib and bevacizumab study expansion cohort. (Q36910794) (← links)
- Precision Oncology: Identifying Predictive Biomarkers for the Treatment of Metastatic Renal Cell Carcinoma (Q37179808) (← links)
- Soluble FAS ligand as a biomarker of disease recurrence in differentiated thyroid cancer (Q37237661) (← links)
- Targeting VEGF in lung cancer (Q37996080) (← links)
- Biomarkers: the next therapeutic hurdle in metastatic renal cell carcinoma (Q38040684) (← links)
- Intrinsic immune alterations in renal cell carcinoma and emerging immunotherapeutic approaches (Q38099023) (← links)
- Molecular targets on the horizon for kidney and urothelial cancer (Q38132039) (← links)
- Targeting angiogenesis in renal cell carcinoma (Q38132231) (← links)
- Biomarkers of renal cell carcinoma (Q38163223) (← links)
- Precision medicine for metastatic renal cell carcinoma (Q38163227) (← links)
- Renal carcinoma pharmacogenomics and predictors of response: Steps toward treatment individualization. (Q38185177) (← links)
- Tivozanib for the treatment of renal cell carcinoma: results and implications of the TIVO-1 trial (Q38261099) (← links)
- C-reactive protein binds to integrin α2 and Fcγ receptor I, leading to breast cell adhesion and breast cancer progression (Q38399277) (← links)
- Predictive molecular biomarkers to guide clinical decision making in kidney cancer: current progress and future challenges (Q38402997) (← links)
- Prognostic factors and risk classifications for patients with metastatic renal cell carcinoma (Q38543085) (← links)
- Predictive biomarker candidates to delineate efficacy of antiangiogenic treatment in renal cell carcinoma (Q38546217) (← links)
- Effects and Side Effects of Using Sorafenib and Sunitinib in the Treatment of Metastatic Renal Cell Carcinoma. (Q38754136) (← links)
- Metastatic clear cell renal cell carcinoma: Circulating biomarkers to guide antiangiogenic and immune therapies. (Q38921098) (← links)
- Circulating biomarkers and outcome from a randomised phase II trial of sunitinib vs everolimus for patients with metastatic renal cell carcinoma. (Q39235567) (← links)
- Integrating cytokines and angiogenic factors and tumour bulk with selected clinical criteria improves determination of prognosis in advanced renal cell carcinoma (Q40132819) (← links)
- Intrinsic resistance to sunitinib in patients with metastatic renal cell carcinoma (Q40826012) (← links)
- Favorable prognostic influence of T-box transcription factor Eomesodermin in metastatic renal cell cancer patients (Q40986108) (← links)
- Plasma cytokine and angiogenic factors associated with prognosis and therapeutic response to sunitinib vs everolimus in advanced non-clear cell renal cell carcinoma (Q41091919) (← links)
- Progression-free survival of first-line treatment with molecular-targeted therapy may be a meaningful intermediate endpoint for overall survival in patients with metastatic renal cell carcinoma (Q41145898) (← links)
- Renal cell carcinoma: the search for a reliable biomarker. (Q41197945) (← links)
- Anti-angiogenic agents in Non-Small-Cell Lung Cancer (NSCLC): a perspective on the MONET1 (Motesanib NSCLC Efficacy and Tolerability) study (Q41768186) (← links)
- Combination of mTOR and MAPK Inhibitors-A Potential Way to Treat Renal Cell Carcinoma (Q42705608) (← links)